Autolus Therapeutics (AUTL) said Friday that the UK Medicines and Healthcare products Regulatory Agency granted conditional marketing authorization for Aucatzyl to treat adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
The authorization is based on results from the Felix study, an open-label, multicenter, single-arm trial in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, according to the company.
The biopharmaceutical company said it submitted obecabtagene autoleucel, an autologous CD19 CAR T cell therapy with a proprietary CD19 CAR, for appraisal by the National Institute for Health and Care Excellence in Q4 2024.
Autolus is currently working with NICE and the NHS to potentially enable access for eligible patients in England.
Shares of Autolus were down 4.3% in recent trading.
Price: 1.34, Change: -0.06, Percent Change: -4.29
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。